Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
Marmorino F, Salvatore L, Barbara C, Allegrini G, Antonuzzo L, Masi G, Loupakis F, Borelli B, Chiara S, Banzi MC, Miraglio E, Amoroso D, Dargenio F, Bonetti A, Martignetti A, Paris M, Tomcikova D, Boni L, Falcone A, Cremolini C. Marmorino F, et al. Among authors: antonuzzo l. Br J Cancer. 2017 Jan;116(3):318-323. doi: 10.1038/bjc.2016.413. Epub 2017 Jan 12. Br J Cancer. 2017. PMID: 28081548 Free PMC article. Clinical Trial.
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry.
Cortellini A, Tabernero J, Mukherjee U, Salazar R, Sureda A, Maluquer C, Ferrante D, Bower M, Sharkey R, Mirallas O, Plaja A, Cucurull M, Mesia R, Dalla Pria A, Newsom-Davis T, Van Hemelrijck M, Sita-Lumsden A, Apthorp E, Vincenzi B, Di Fazio GR, Tonini G, Pantano F, Bertuzzi A, Rossi S, Brunet J, Lambertini M, Pedrazzoli P, Biello F, D'Avanzo F, Lee AJX, Shawe-Taylor M, Rogers L, Murphy C, Cooper L, Andaleeb R, Khalique S, Bawany S, Ahmed S, Carmona-García MC, Fort-Culillas R, Liñan R, Zoratto F, Rizzo G, Perachino M, Doonga K, Gaidano G, Bruna R, Patriarca A, Martinez-Vila C, Pérez Criado I, Giusti R, Mazzoni F, Antonuzzo L, Santoro A, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Diamantis N, Bertulli R, Fulgenzi CAM, D'Alessio A, Ruiz-Camps I, Saoudi-Gonzalez N, Garcia Illescas D, Medina I, Fox L, Gennari A, Aguilar-Company J, Pinato DJ; OnCovid study group. Cortellini A, et al. Among authors: antonuzzo l. Lancet Oncol. 2023 Apr;24(4):335-346. doi: 10.1016/S1470-2045(23)00056-6. Epub 2023 Mar 7. Lancet Oncol. 2023. PMID: 36898391 Free PMC article.
Classic and Follicular Variant of Papillary Thyroid Microcarcinoma: 2 Different Phenotypes Beyond Tumor Size.
Sparano C, Rotondi M, Verdiani V, Brunori P, Castiglione F, Bartoli C, Perigli G, Badii B, Vezzosi V, Simontacchi G, Livi L, Antonuzzo L, Maggi M, Petrone L. Sparano C, et al. Among authors: antonuzzo l. J Endocr Soc. 2022 Oct 13;6(12):bvac157. doi: 10.1210/jendso/bvac157. eCollection 2022 Oct 26. J Endocr Soc. 2022. PMID: 36397778 Free PMC article.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; Italian Oncology Group for Cancer Research; Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R. Di Costanzo F, et al. Among authors: antonuzzo l. J Natl Cancer Inst. 2008 Mar 19;100(6):388-98. doi: 10.1093/jnci/djn054. Epub 2008 Mar 11. J Natl Cancer Inst. 2008. PMID: 18334706 Clinical Trial.
Bevacizumab in non-small cell lung cancer.
Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M, Di Costanzo F. Di Costanzo F, et al. Among authors: antonuzzo l. Drugs. 2008;68(6):737-46. doi: 10.2165/00003495-200868060-00002. Drugs. 2008. PMID: 18416583 Review.
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F. Inghilesi AL, et al. Among authors: antonuzzo l. World J Gastroenterol. 2014 Jan 21;20(3):786-94. doi: 10.3748/wjg.v20.i3.786. World J Gastroenterol. 2014. PMID: 24574751 Free PMC article.
Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G. Panzuto F, et al. Among authors: antonuzzo l. Oncologist. 2014 Sep;19(9):966-74. doi: 10.1634/theoncologist.2014-0037. Epub 2014 Aug 12. Oncologist. 2014. PMID: 25117065 Free PMC article. Clinical Trial.
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, Granetto C, Fea E, Antonuzzo L, Boni C, Allegrini G, Chiara S, Amoroso D, Bonetti A, Falcone A; BEBYP Study Investigators. Masi G, et al. Among authors: antonuzzo l. Ann Oncol. 2015 Apr;26(4):724-730. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18. Ann Oncol. 2015. PMID: 25600568 Free article. Clinical Trial.
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Antonuzzo L, et al. World J Gastroenterol. 2015 Jun 21;21(23):7281-8. doi: 10.3748/wjg.v21.i23.7281. World J Gastroenterol. 2015. PMID: 26109816 Free PMC article. Clinical Trial.
176 results